Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Sophia Genetics Affirms FY2025 Sales Guidance of $72.000M-$76.000M vs $74.200M Est; Projects Adjusted EBITDA Loss Between $35M-$39M

Author: Benzinga Newsdesk | August 05, 2025 05:48am
Sophia Genetics (NASDAQ:SOPH) affirms FY2025 sales outlook from $72.000 million-$76.000 million to $72.000 million-$76.000 million vs $74.200 million estimate.

Posted In: SOPH


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist